Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Roche v. Organon Teknika

This article was originally published in The Gray Sheet

Executive Summary

Roche v. Organon Teknika: Roche files suit against Organon Teknika alleging that Teknika's NASBA gene amplification technology used in two HIV tests available in Europe infringes Roche's European patent for polymerase chain reaction amplification technology. The suit, filed in the District Court in The Hague, the Netherlands, seeks to prohibit Teknika from marketing the quantitative and qualitative HIV test kits in Europe, as well as any future assays using the NASBA technology. Teknika "has carefully studied and evaluated" Roche's PCR patent "and has concluded that [the patent] bears no relevance to the NASBA tests," the company says. Teknika, which has "a number" of patents for NASBA, is currently developing 10 additional assays based on the technology, including a test for tuberculosis...

You may also be interested in...



QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.

UsernamePublicRestriction

Register

MT004681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel